Literature DB >> 3717017

High-dose, brief-duration intravenous infusion of streptokinase in acute myocardial infarction: description of effects in the circulation.

R L Mentzer, A Z Budzynski, S Sherry.   

Abstract

The effects in the circulating blood of a 1-hour intravenous infusion of 1.5 X 10(6) units of streptokinase (SK) were measured during the subsequent 24-hour period in 7 patients with acute myocardial infarction. At the end of the infusion, the activator activity, expressed in SK units, averaged 65 U/ml, all of the plasminogen had disappeared, only a small amount of free plasmin was still present and functionally active alpha 2 antiplasmin had been reduced to 21% of the preinfusion level. All of the native fibrinogen had been degraded and the thrombin-coagulable protein was composed entirely of fragment X species, but the circulating plasma also contained significant amounts of the more extensively degraded fragments Y, D and E. The biologic half-life of the SK-induced activator activity was 23 minutes and that of the fibrinogen degradation products was 6.3 hours. The lytic effects persisted for 4 hours before any signs of recovery from the hemostatic defect were evident; considerable recovery was present at 25 hours.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3717017     DOI: 10.1016/0002-9149(86)90192-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  10 in total

1.  Thrombolytic therapy for acute myocardial infarction. Lessons to be learned.

Authors:  S Sherry
Journal:  Tex Heart Inst J       Date:  1991

Review 2.  Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction.

Authors:  K L Goa; J M Henwood; J F Stolz; M S Langley; S P Clissold
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator.

Authors:  J Owen; K D Friedman; B A Grossman; C Wilkins; A D Berke; E R Powers
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

4.  Pharmacokinetic properties of anisoylated plasminogen streptokinase activator complex and other thrombolytic agents in animals and in humans.

Authors:  B Nunn; A Esmail; R Fears; H Ferres; R Standring
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  The protective effect of acylation on the stability of anisoylated plasminogen streptokinase activator complex in human plasma.

Authors:  R Fears; H Ferres; R Standring
Journal:  Drugs       Date:  1987       Impact factor: 9.546

6.  Biological study of intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.

Authors:  M Samama; J Conard; E Verdy; P van Dreden; G Nguyen; A Combrisson; J Acar
Journal:  Drugs       Date:  1987       Impact factor: 9.546

7.  A comparison of the pharmacokinetic properties of streptokinase and anistreplase in acute myocardial infarction.

Authors:  J D Gemmill; K J Hogg; J M Burns; A P Rae; F G Dunn; R Fears; H Ferres; R Standring; H Greenwood; D Pierce
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

Review 8.  Pharmacokinetic optimisation of the treatment of embolic disorders.

Authors:  D M Lutomski; M Bottorff; K Sangha
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

9.  The membrane attack complex of complement contributes to plasmin-induced synthesis of platelet-activating factor by endothelial cells and neutrophils.

Authors:  Enrico Lupia; Lorenzo Del Sorbo; Serena Bergerone; Giorgio Emanuelli; Giovanni Camussi; Giuseppe Montrucchio
Journal:  Immunology       Date:  2003-08       Impact factor: 7.397

Review 10.  Streptokinase. A review of its pharmacology and therapeutic efficacy in acute myocardial infarction in older patients.

Authors:  P E Battershill; P Benfield; K L Goa
Journal:  Drugs Aging       Date:  1994-01       Impact factor: 3.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.